ProjektIMAGIO – Imaging and advanced guidance for workflow optimization in interventional oncology
Grunddaten
Akronym:
IMAGIO
Titel:
Imaging and advanced guidance for workflow optimization in interventional oncology
Laufzeit:
01.05.2023 bis 30.04.2027
Abstract / Kurz- beschreibung:
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Lung and
liver cancers were among the top three leading causes of cancer death in 2020 with 1.8 million and 830.000 deaths, respectively. On
the other hand, soft tissue sarcomas are relatively uncommon cancers diagnosed in about 1% of all adults, but much more common
in children and young adults, accounting for 7–10% of paediatric malignancies; they are an important cause of death in the 14–29
years age group.
Interventional Oncology (IO) involves miniaturized instruments (biopsy needles, ablation electrodes, intravascular catheters) and
minimally-invasive access, guided by imaging techniques (X-ray, ultrasound, computed tomography, magnetic resonance imaging) –
to target cancer with ablative or localized drug delivery strategies. IO can be used as a stand-alone approach, or in combination with
the other approaches (‘pillars’) to enhance treatment efficacy.
While cancer survival has significantly improved over time through innovations in each individual pillar, our current understanding of
cancer now leads us to an intertwining of pillars and multimodal care pathways: IO is uniquely suited to leverage and enhance the
effects of the conventional therapy pillars, while reducing the burden on the healthcare system.
IMAGIO will leverage IO in the clinical setting to improve the cancer survival outcomes, through minimally invasive, efficient, and
affordable care pathways for three disease states: liver cancer, lung cancer and sarcoma. In IMAGIO, top innovators in MedTech and
Pharma will mature the next-generation IO imaging across the full spectrum, from pre-clinical developments to impact validation in
clinical trials. IO and immunotherapy expertise will be leveraged from top MedTech and Pharma partners covering the full value chain
of oncological care – to provide cancer patients access to safe, fast, and effective care.
liver cancers were among the top three leading causes of cancer death in 2020 with 1.8 million and 830.000 deaths, respectively. On
the other hand, soft tissue sarcomas are relatively uncommon cancers diagnosed in about 1% of all adults, but much more common
in children and young adults, accounting for 7–10% of paediatric malignancies; they are an important cause of death in the 14–29
years age group.
Interventional Oncology (IO) involves miniaturized instruments (biopsy needles, ablation electrodes, intravascular catheters) and
minimally-invasive access, guided by imaging techniques (X-ray, ultrasound, computed tomography, magnetic resonance imaging) –
to target cancer with ablative or localized drug delivery strategies. IO can be used as a stand-alone approach, or in combination with
the other approaches (‘pillars’) to enhance treatment efficacy.
While cancer survival has significantly improved over time through innovations in each individual pillar, our current understanding of
cancer now leads us to an intertwining of pillars and multimodal care pathways: IO is uniquely suited to leverage and enhance the
effects of the conventional therapy pillars, while reducing the burden on the healthcare system.
IMAGIO will leverage IO in the clinical setting to improve the cancer survival outcomes, through minimally invasive, efficient, and
affordable care pathways for three disease states: liver cancer, lung cancer and sarcoma. In IMAGIO, top innovators in MedTech and
Pharma will mature the next-generation IO imaging across the full spectrum, from pre-clinical developments to impact validation in
clinical trials. IO and immunotherapy expertise will be leveraged from top MedTech and Pharma partners covering the full value chain
of oncological care – to provide cancer patients access to safe, fast, and effective care.
Schlüsselwörter:
Imaging, image and data processing
Clinical management
Oncology
Radiology, nuclear medicine and medical imaging
Health services, health care research
Beteiligte Mitarbeiter/innen
Leiter/innen
Medizinische Fakultät
Universität Tübingen
Universität Tübingen
Exzellenzcluster: Individualisierung von Tumortherapien durch molekulare Bildgebung und funktionelle Identifizierung therapeutischer Zielstrukturen (iFIT)
Zentren oder interfakultäre wissenschaftliche Einrichtungen
Zentren oder interfakultäre wissenschaftliche Einrichtungen
Weitere Mitarbeiter/innen
Medizinische Fakultät
Universität Tübingen
Universität Tübingen
Lokale Einrichtungen
Abteilung Präklinische Bildgebung und Radiopharmazie
Radiologische Universitätsklinik (Department)
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Geldgeber
Brüssel, Belgien